View on market: Volatility persists, eagerly searching for growth:
Asian markets opened lower as renewed fighting in the Middle East increased investor concerns and weakened market sentiment. Fresh military exchanges between the US and Iran, including developments around the Strait of Hormuz, raised fears of further regional instability and possible disruption to global trade and energy supplies. US markets ended on a weaker note as investors reacted to the renewed tensions between the US and Iran. The uncertainty encouraged a cautious approach among investors and put pressure on major US indices. Indian equity markets also ended lower in the previous session. Selling pressure was mainly seen in metal and IT stocks, which dragged the benchmark indices down. Overall, global markets remain under pressure as geopolitical tensions continue to create uncertainty and investors closely monitor developments in the Middle East.
Economic Calendar:
- USD: S&P Global and ISM Manufacturing PMI Data on 01st September 2026.
- IND: S&P Global Manufacturing PMI and Monthly Auto Sales for August Data on 01st September 2026.
- USD: Export & Import, Initial & Continuing Jobless Claim, S&P Global Composite & Services PMI and ISM Services PMI Data on 03rd September 2026.
- IND: S&P Global Services and Composite PMI on 03rd September 2026.
BROKERAGE
UBS ON IDFC FIRST:
Target ₹92 Earlier Target ₹78 Recommendation Neutral, Improving earnings outlook, Asset quality outlook improving, but high C/I ratio limits RoA expansion, Branch expansion to support loan growth; margins to remain stable, Asset quality improving, but likely already priced in, Expect growth to pick up gradually in the high yielding book, though it is likely to lag overall loan growth, Consequently, NIMs are likely to remain stable at 5.8% over FY27-29.
GOLDMAN SACHS ON ICICI BANK:
Target ₹1935 Recommendation Accumulate, Management highlighted that loan growth remains strong, helped by MSME segment and pickup in secured as well as unsecured retail loans, Bank has sustained strong market share in FCNR (B) deposit mobilization which is expected to be earnings accretive, Overseas NIM will moderate given self-funded FCNR (B) deposit-related loans.
GOLDMAN SACHS ON HYUNDAI:
Target ₹2640 Recommendation Accumulate, Expect H2FY27 industry growth on high base + margin levers, To launch compact EV in Q4 and compete in the Nexon segment, All Hyundai EV model will be PLI compliant from day one, New Mid Size SUV expected to be in the Creta category but will be a technology first/Software Defined Vehicle, to be launched.
JEFFERIES ON RIL:
Target ₹1710 Earlier Target ₹1705 Recommendation Accumulate, O2C Strength Supports FY27 Earnings, 4% of global refinery throughput has been lost due to conflicts resulting in diesel and gasoline inventories falling to 5-year lows, Singapore GRM prevails near life-high as a result, The tightness could last through CY2026, Petchem spreads remain firm supporting O2C earnings growth in FY27E.
International Markets:
U.S & Europe:
| Particulars | 31st Aug | Chg. | Chg.(%) |
| Nasdaq | 26,370.89 | -31.53 | -0.12 |
| Dow | 53,185.90 | -374.09 | -0.70 |
| FTSE** | 10,824.26 | 31.72 | 0.29 |
| CAC | 8,334.50 | -66.68 | -0.79 |
| DAX | 26,258.11 | -311.88 | -1.17 |
| Dow Fut.* | 53,252.56 | 66.66 | 0.13 |
*As per 01st September.
Asian markets:
| Particulars | 01st Sept | Chg. | Chg.(%) |
| GIFT Nifty | 24,186.50 | -58.50 | -0.24 |
| Nikkei | 66,017.00 | -294.93 | -0.44 |
| Straits Times | 5,717.20 | -38.16 | -0.66 |
| Hang Seng | 25,227.00 | -339.99 | -1.33 |
| Taiwan Weighted | 46,753.20 | 624.73 | 1.35 |
| KOSPI | 6,770.82 | -49.20 | -0.72 |
| Shanghai | 3,977.94 | -8.36 | -0.21 |
Stocks strong on Chart:
| Index | F&O | Cash |
| AXISBANK | AUROPHARMA | BODALCHEM |
| BEL | INDHOTEL | CORDSCABLE |
| ICICIBANK | NYKAA | KOPRAN |
| SBIN | PAYTM | LOKESHMACH |
| SHRIRAMFIN | PIDILITIND | PAR |
| SUNPHARMA | POLYCAB | PARAGMILK |
Commodities & Currency:
| Particulars | Current Price | Chg. (%) |
| USD/INR | 95.17 | -0.23 |
| Brent | 91.204 | 0.79 |
| Gold | 154,456.00 | 0.00 |
| Silver | 233,977.00 | 0.06 |
FIIs & DIIs:
| Particulars | 31st Aug | 28th Aug |
| FIIs | -7,985.88 | -5,039.80 |
| DIIs | 4,588.88 | 5,183.93 |
News Updates:
| Cipla: | Signs an exclusive licence with SBP Group to develop and supply Rolditamig Deuderuxtecan, a HER2 ADC, in India, South Africa and five other markets. |
| Sun Pharma: | Signed a White House agreement extending MFN drug pricing to US Medicaid programs, securing a two-year tariff delay as it acquires Organon for $11.75B. |
| E2E Networks | Signs a binding term sheet with an India-based sovereign AI company to supply NVIDIA Blackwell cloud GPUs and allied services. Contract value is approximately ₹1,000 crore and remains valid through June 2029. |
| Indo Tech Transformers: | Wins an order worth ₹55 crore from Waaree Renewable Technologies for five transformers, with execution scheduled by April 2027. |
| Muthoot Finance: | Board approves the scheme of amalgamation of its wholly owned subsidiary, Muthoot Money, with Muthoot Finance. |
| PVR INOX: | Board approves a ₹300 crore buyback of 20.69 lakh shares at ₹1,450 per share. Record date fixed for Sept. 4, 2026. |
| Jindal Worldwide: | Jindal Mobilitric plans to expand its retail network to 100 showrooms by FY28, strengthening its nationwide EV presence. |
Source: Moneycontrol, Bloomberg Quint, Investing
View on market: Volatility persists, eagerly searching for growth
Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014
- InCred Markets Limited (“the Company”), Formerly known as Elite Wealth Limited (The company is Wholly Owned Subsidiary of InCred Capital Financial Services Limited) does/ does not do business with companies covered in its research reports. Investors should be aware that the Company may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by the Company are registered/qualified as research analysts with SEBI in India. (SEBI Registration No.: INH100002300)Disclosure AppendixAnalyst Certification (For Reports)Vindhyachal Prasad, InCred Markets Limited, vindhyachal@elitestock.comThe analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in the Company.As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:
- All of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
- No part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.Company-Specific Disclosures
Important disclosures, including price charts, are available and all InCred Markets Limited covered companies by visiting https://www.elitewealth.in, or emailing research@elitestock.com with your request. The Company may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.inOther Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.Ownership and material conflicts of interest Disclosure
InCred Markets Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of the Company. Analyst as officer or director: The Company’s policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.Country Specific Disclosures
India – For private circulation only, not for sale. LegalEntities Disclosures
InCred Markets Limited (Formerly known as Elite Wealth Limited) (IML henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone: 011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.inThe Company discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:
- Reports
- IML or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
- IML or its associates or relatives, have no actual/beneficial ownership of one %. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;
- IML or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;
- Compensation
- IML or its associates have not received any compensation from the subject company in the past twelve months;
- IML or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
- IML or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
- IML or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;
- IML or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research
- In respect of Public Appearances
- IML or its associates have not received any compensation from the subject company in the past twelve months;
- The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by IML
